Last 12 months
Inside the activity.
1 purchase rows · 173 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 6 |
| Jan 2026 | 0 | 10 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 16 |
| Apr 2026 | 0 | 23 |
| May 2026 | 1 | 24 |
| Jun 2026 | 0 | 37 |
| Jul 2026 | 0 | 33 |
| Aug 2026 | 0 | 6 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 10 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2022 Filed Apr 20, 2022 20:37 UTC |
Schundler RussellGeneral Counsel
|
GrantCommon Stock | 2,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-047873 · tm2213052-5_4seq1.xml · nonDerivative · entry 1 Schundler Russell · CIK 0001854414 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,746 F1 · acquired: On March 31, 2022, 2,158 shares of the Issuer's common stock which were previously subject to a holdback pursuant to the terms of the merger agreement for Issuer's acquisition of RareGen, LLC ("RareGen") were released to the Reporting Person. The merger agreement provided that certain shares of the Issuer's common stock issuable to members of RareGen at the closing of the transaction would be held back as partial security for the benefit of the Issuer with respect to any indemnifiable damages pursuant to the indemnification obligations of the members of RareGen. The shares would subsequently be released for no additional consideration, subject to the cancellation of shares of the Issuer's common stock in connection with any such indemnifiable damages. Read SEC document |
| March 31, 2022 Filed Apr 20, 2022 20:36 UTC |
Manning Paul BDirector
|
GrantCommon Stock | 435,674 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-047871 · tm2213052-4_4seq1.xml · nonDerivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 435,674 F1 · kind: On March 31, 2022, 435,674 shares of the Issuer's common stock which were previously subject to a holdback pursuant to the terms of the merger agreement for Issuer's acquisition of RareGen, LLC ("RareGen") were released to the Reporting Person. The merger agreement provided that certain shares of the Issuer's common stock issuable to members of RareGen at the closing of the transaction would be held back as partial security for the benefit of the Issuer with respect to any indemnifiable damages pursuant to the indemnification obligations of the members of RareGen. The shares would subsequently be released for no additional consideration, subject to the cancellation of shares of the Issuer's common stock in connection with any such indemnifiable damages. F2 · ownership.nature: The securities are held by PBM Capital Finance, LLC ("PBM"). The Reporting Person is the manager and sole beneficial owner of PBM. Read SEC document |
| March 31, 2022 Filed Apr 20, 2022 20:35 UTC |
JEFFS ROGERDirector · Chief Executive Officer
|
GrantCommon Stock | 154,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-047869 · tm2213052-2_4seq1.xml · nonDerivative · entry 1 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,541,667 F1 · kind: On March 31, 2022, 154,167 shares of the Issuer's common stock which were previously subject to a holdback pursuant to the terms of the merger agreement for Issuer's acquisition of RareGen, LLC ("RareGen") were released to the Reporting Person. The merger agreement provided that certain shares of the Issuer's common stock issuable to members of RareGen at the closing of the transaction would be held back as partial security for the benefit of the Issuer with respect to any indemnifiable damages pursuant to the indemnification obligations of the members of RareGen. The shares would subsequently be released for no additional consideration, subject to the cancellation of shares of the Issuer's common stock in connection with any such indemnifiable damages. F2 · ownership.nature: The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. Read SEC document |
| March 31, 2022 Filed Apr 20, 2022 20:36 UTC |
deGoa DamianDirector
|
GrantCommon Stock | 4,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-047870 · tm2213052-3_4seq1.xml · nonDerivative · entry 1 deGoa Damian · CIK 0001836165 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,716 F1 · acquired: On March 31, 2022, 4,625 shares of the Issuer's common stock which were previously subject to a holdback pursuant to the terms of the merger agreement for Issuer's acquisition of RareGen, LLC ("RareGen") were released to the Reporting Person. The merger agreement provided that certain shares of the Issuer's common stock issuable to members of RareGen at the closing of the transaction would be held back as partial security for the benefit of the Issuer with respect to any indemnifiable damages pursuant to the indemnification obligations of the members of RareGen. The shares would subsequently be released for no additional consideration, subject to the cancellation of shares of the Issuer's common stock in connection with any such indemnifiable damages. Read SEC document |
| January 16, 2022 Filed Jan 19, 2022 21:35 UTC |
Schundler RussellGeneral Counsel
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0001104659-22-005472 · tm221559-5_4seq1.xml · derivative · entry 2 Schundler Russell · CIK 0001854414 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-01-16 F3 · derivative.exercise_date: The options will vest ratably on a monthly basis over four years with the first vesting date to occur on February 28, 2022 and on the last day of each month thereafter. Read SEC document |
| January 16, 2022 Filed Jan 19, 2022 21:35 UTC |
Schundler RussellGeneral Counsel
|
GrantRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005472 · tm221559-5_4seq1.xml · derivative · entry 1 Schundler Russell · CIK 0001854414 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 25% of the RSUs shall vest on February 28, 2023 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter. F2 · derivative.expiration_date: 25% of the RSUs shall vest on February 28, 2023 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter. Read SEC document |
| January 16, 2022 Filed Jan 19, 2022 16:36 UTC |
Shah TusharCMO and Head of R&D
|
GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0001104659-22-005473 · tm221559-6_4seq1.xml · derivative · entry 2 Shah Tushar · CIK 0001487632 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-01-16 F3 · derivative.exercise_date: The options will vest ratably on a monthly basis over four years with the first vesting date to occur on February 28, 2022 and on the last day of each month thereafter. Read SEC document |
| January 16, 2022 Filed Jan 19, 2022 16:36 UTC |
Shah TusharCMO and Head of R&D
|
GrantRestricted Stock Units · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005473 · tm221559-6_4seq1.xml · derivative · entry 1 Shah Tushar · CIK 0001487632 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 25% of the RSUs shall vest on February 28, 2023 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter. F2 · derivative.expiration_date: 25% of the RSUs shall vest on February 28, 2023 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter. Read SEC document |
| January 16, 2022 Filed Jan 19, 2022 16:34 UTC |
Lippe Robert AChief Operations Officer
|
GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0001104659-22-005470 · tm221559-3_4seq1.xml · derivative · entry 2 Lippe Robert A · CIK 0001600757 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2032-01-16 F3 · derivative.exercise_date: The options will vest ratably on a monthly basis over four years with the first vesting date to occur on February 28, 2022 and on the last day of each month thereafter. Read SEC document |
| January 16, 2022 Filed Jan 19, 2022 16:34 UTC |
Lippe Robert AChief Operations Officer
|
GrantRestricted Stock Units · Derivative | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005470 · tm221559-3_4seq1.xml · derivative · entry 1 Lippe Robert A · CIK 0001600757 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 25% of the RSUs shall vest on February 28, 2023 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter. F2 · derivative.expiration_date: 25% of the RSUs shall vest on February 28, 2023 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter. Read SEC document |
| January 16, 2022 Filed Jan 19, 2022 21:33 UTC |
Kaseta MichaelChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0001104659-22-005469 · tm221559-2_4seq1.xml · derivative · entry 2 Kaseta Michael · CIK 0001724346 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-01-16 F3 · derivative.exercise_date: The options will vest ratably on a monthly basis over four years with the first vesting date to occur on February 28, 2022 and on the last day of each month thereafter. Read SEC document |
| January 16, 2022 Filed Jan 19, 2022 21:33 UTC |
Kaseta MichaelChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005469 · tm221559-2_4seq1.xml · derivative · entry 1 Kaseta Michael · CIK 0001724346 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 25% of the RSUs shall vest on February 28, 2023 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter. F2 · derivative.expiration_date: 25% of the RSUs shall vest on February 28, 2023 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter. Read SEC document |
| January 16, 2022 Filed Jan 19, 2022 21:34 UTC |
Moomaw ScottSVP, Commercial
|
GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0001104659-22-005471 · tm221559-4_4seq1.xml · derivative · entry 2 Moomaw Scott · CIK 0001832592 · SVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-01-16 F3 · derivative.exercise_date: The options will vest ratably on a monthly basis over four years with the first vesting date to occur on February 28, 2022 and on the last day of each month thereafter. Read SEC document |
| January 16, 2022 Filed Jan 19, 2022 21:34 UTC |
Moomaw ScottSVP, Commercial
|
GrantRestricted Stock Units · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-005471 · tm221559-4_4seq1.xml · derivative · entry 1 Moomaw Scott · CIK 0001832592 · SVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: 25% of the RSUs shall vest on February 28, 2023 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter. F2 · derivative.expiration_date: 25% of the RSUs shall vest on February 28, 2023 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 22:05 UTC |
JEFFS ROGERDirector · Chief Executive Officer
|
GrantRestricted Stock Unit · Derivative | 63,230 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-000972 · tm221559-1_4seq1.xml · derivative · entry 2 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,230 Underlying: Common Stock · 63,230 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a right to receive one share of the Issuer's common shares without payment of specific consideration. F3 · derivative.exercise_date: 25% of the grant will become vested quarterly through the first anniversary of the transaction date. F4 · derivative.expiration_date: Not applicable. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 22:05 UTC |
JEFFS ROGERDirector · Chief Executive Officer
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,682,827 | $0.00 Strike: $5.14 | $0.00 |
DisclosureSEC source: 0001104659-22-000972 · tm221559-1_4seq1.xml · derivative · entry 1 JEFFS ROGER · CIK 0001231615 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,763,180 Underlying: Common Stock · 1,682,827 shares Expires 2032-01-03 F1 · derivative.exercise_date: 25% of the grant will become vested and exercisable or settled, as applicable, on first anniversary of the transaction date and the balance will become vested and exercisable or settled, as applicable, in equal monthly installments over the following thirty-six (36) months. Read SEC document |
| November 12, 2021 Filed Nov 12, 2021 21:03 UTC |
Shah TusharCMO and Head of R&D
|
Tax withholdingCommon Stock | 11,882 | $4.90 | $58,203.98 |
DisclosureSEC source: 0001104659-21-138343 · tm2132597-6_4seq1.xml · nonDerivative · entry 3 Shah Tushar · CIK 0001487632 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,881 Read SEC document |
| November 12, 2021 Filed Nov 12, 2021 21:03 UTC |
Shah TusharCMO and Head of R&D
|
Tax withholdingCommon Stock | 487 | $5.05 | $2,456.92 |
DisclosureSEC source: 0001104659-21-138343 · tm2132597-6_4seq1.xml · nonDerivative · entry 2 Shah Tushar · CIK 0001487632 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,763 Read SEC document |
| November 12, 2021 Filed Nov 12, 2021 20:18 UTC |
Lippe Robert AChief Operations Officer
|
Tax withholdingCommon Stock | 518 | $5.04 | $2,610.72 |
DisclosureSEC source: 0001104659-21-138330 · tm2132597-5_4seq1.xml · nonDerivative · entry 3 Lippe Robert A · CIK 0001600757 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,480 Read SEC document |
| November 12, 2021 Filed Nov 12, 2021 20:18 UTC |
Lippe Robert AChief Operations Officer
|
Tax withholdingCommon Stock | 12,612 | $4.90 | $61,779.88 |
DisclosureSEC source: 0001104659-21-138330 · tm2132597-5_4seq1.xml · nonDerivative · entry 2 Lippe Robert A · CIK 0001600757 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,998 Read SEC document |
| November 10, 2021 Filed Nov 10, 2021 23:01 UTC |
Schundler RussellGeneral Counsel
|
PurchaseCommon Stock | 60,000 | $4.18 | $250,590.00 |
DisclosureSEC source: 0001104659-21-137081 · tm2132597-1_4seq1.xml · nonDerivative · entry 3 Schundler Russell · CIK 0001854414 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,588 Read SEC document |
| November 10, 2021 Filed Nov 10, 2021 23:01 UTC |
Schundler RussellGeneral Counsel
|
PurchaseCommon Stock | 39,900 | $4.28 | $170,648.31 |
DisclosureSEC source: 0001104659-21-137081 · tm2132597-1_4seq1.xml · nonDerivative · entry 2 Schundler Russell · CIK 0001854414 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,588 Read SEC document |
| November 10, 2021 Filed Nov 10, 2021 23:01 UTC |
Schundler RussellGeneral Counsel
|
PurchaseCommon Stock | 18,008 | $4.20 | $75,595.78 |
DisclosureSEC source: 0001104659-21-137081 · tm2132597-1_4seq1.xml · nonDerivative · entry 1 Schundler Russell · CIK 0001854414 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,688 Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:03 UTC |
Shah TusharCMO and Head of R&D
|
GrantPerformance Stock Units · Derivative | 51,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-138343 · tm2132597-6_4seq1.xml · derivative · entry 4 Shah Tushar · CIK 0001487632 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,250 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit (PSU) converts into one share of common stock of the Issuer. F2 · derivative.exercise_date: On January 19, 2021, the reporting person was granted 51,250 PSUs, vesting in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. F2 · derivative.expiration_date: On January 19, 2021, the reporting person was granted 51,250 PSUs, vesting in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:03 UTC |
Shah TusharCMO and Head of R&D
|
Exercise / conversionCommon Stock | 51,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-138343 · tm2132597-6_4seq1.xml · nonDerivative · entry 1 Shah Tushar · CIK 0001487632 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance stock unit (PSU) converts into one share of common stock of the Issuer. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 21:16 UTC |
KIRSCH ARTHUR SDirector
|
PurchaseCommon Stock | 30,000 | $4.24 | $127,200.00 |
DisclosureSEC source: 0001104659-21-138087 · tm2132597-2_4seq1.xml · nonDerivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.18 to $4.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 20:18 UTC |
Lippe Robert AChief Operations Officer
|
GrantPerformance Stock Units · Derivative | 51,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-138330 · tm2132597-5_4seq1.xml · derivative · entry 4 Lippe Robert A · CIK 0001600757 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,250 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit (PSU) converts into one share of common stock of the Issuer. F2 · derivative.exercise_date: On January 19, 2021, the reporting person was granted 51,250 PSUs, vesting in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. F2 · derivative.expiration_date: On January 19, 2021, the reporting person was granted 51,250 PSUs, vesting in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 20:18 UTC |
Lippe Robert AChief Operations Officer
|
Exercise / conversionCommon Stock | 51,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-138330 · tm2132597-5_4seq1.xml · nonDerivative · entry 1 Lippe Robert A · CIK 0001600757 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance stock unit (PSU) converts into one share of common stock of the Issuer. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 23:59 UTC |
Kaseta MichaelChief Financial Officer
|
GrantPerformance Stock Units · Derivative | 9,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-138291 · tm2132597-3_4seq1.xml · derivative · entry 2 Kaseta Michael · CIK 0001724346 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,250 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit (PSU) converts into one share of common stock of the Issuer. F2 · derivative.exercise_date: On January 19, 2021, the reporting person was granted 9,250 PSUs, vesting in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. F2 · derivative.expiration_date: On January 19, 2021, the reporting person was granted 9,250 PSUs, vesting in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 23:59 UTC |
Kaseta MichaelChief Financial Officer
|
Exercise / conversionCommon Stock | 9,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-138291 · tm2132597-3_4seq1.xml · nonDerivative · entry 1 Kaseta Michael · CIK 0001724346 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance stock unit (PSU) converts into one share of common stock of the Issuer. Read SEC document |
| November 10, 2021 Filed Nov 13, 2021 00:11 UTC |
Moomaw ScottSVP, Commercial
|
GrantPerformance Stock Units · Derivative | 7,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-138300 · tm2132597-4_4seq1.xml · derivative · entry 2 Moomaw Scott · CIK 0001832592 · SVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,650 shares Expires not disclosed F1 · derivative.exercise_price: Each performance stock unit (PSU) converts into one share of common stock of the Issuer. F2 · derivative.exercise_date: On January 19, 2021, the reporting person was granted 7,650 PSUs, vesting in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. F2 · derivative.expiration_date: On January 19, 2021, the reporting person was granted 7,650 PSUs, vesting in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861. Read SEC document |
| November 10, 2021 Filed Nov 13, 2021 00:11 UTC |
Moomaw ScottSVP, Commercial
|
Exercise / conversionCommon Stock | 7,650 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-138300 · tm2132597-4_4seq1.xml · nonDerivative · entry 1 Moomaw Scott · CIK 0001832592 · SVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance stock unit (PSU) converts into one share of common stock of the Issuer. Read SEC document |
| September 07, 2021 Filed Feb 15, 2022 02:16 UTC |
Manning Paul BDirector · 10% owner
|
GiftCommon Stock | 4,460,308 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009600 · doc5.xml · nonDerivative · entry 4 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,460,308 F3 · ownership.direct: The shares of are held by Reporting Person jointly with his spouse. Read SEC document |
| September 07, 2021 Filed Feb 15, 2022 02:16 UTC |
Manning Paul BDirector · 10% owner
|
GiftCommon Stock | 4,460,308 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009600 · doc5.xml · nonDerivative · entry 3 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 198,413 F2 · ownership.nature: The securities are held by PD Joint Holdings, LLC Series 2016-A ("PD"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC ("Tiger Lily"), the manager of PD, and has shared voting and investment power with respect to the shares held by PD. Read SEC document |
| August 20, 2021 Filed Sep 1, 2021 21:26 UTC |
SINGH RAMANDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001104659-21-112114 · tm2126786-8_4seq1.xml · derivative · entry 1 SINGH RAMAN · CIK 0001747589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-08-20 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will become fully vested on August 20, 2024. Read SEC document |
| August 20, 2021 Filed Sep 1, 2021 21:24 UTC |
Manning Paul BDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001104659-21-112108 · tm2126786-6_4seq1.xml · derivative · entry 1 Manning Paul B · CIK 0001494695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-08-20 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will become fully vested on August 20, 2024. Read SEC document |
| August 20, 2021 Filed Sep 1, 2021 21:22 UTC |
KIRSCH ARTHUR SDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001104659-21-112104 · tm2126786-5_4seq1.xml · derivative · entry 1 Kirsch Arthur S · CIK 0001290976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-08-20 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will become fully vested on August 20, 2024. Read SEC document |
| August 20, 2021 Filed Sep 1, 2021 21:25 UTC |
JEFFS ROGERDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001104659-21-112112 · tm2126786-3_4.xml · derivative · entry 1 JEFFS ROGER · CIK 0001231615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-08-20 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will become fully vested on August 20, 2024. Read SEC document |
| August 20, 2021 Filed Sep 1, 2021 21:23 UTC |
Bloch Stephen MDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001104659-21-112107 · tm2126786-1_4seq1.xml · derivative · entry 1 Bloch Stephen M · CIK 0001400308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-08-20 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will become fully vested on August 20, 2024. Read SEC document |
| August 20, 2021 Filed Sep 1, 2021 21:25 UTC |
Horobin JoannaDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001104659-21-112110 · tm2126786-2_4seq1.xml · derivative · entry 1 Horobin Joanna · CIK 0001560959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-08-20 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will become fully vested on August 20, 2024. Read SEC document |
| August 20, 2021 Filed Sep 1, 2021 21:27 UTC |
JOHNSON DAVID EDWARDDirector · 10% owner
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001104659-21-112115 · tm2126786-4_4seq1.xml · derivative · entry 1 JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-08-20 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will become fully vested on August 20, 2024. Read SEC document |
| August 20, 2021 Filed Sep 1, 2021 21:25 UTC |
Rielly-Gauvin KatherineDirector
|
GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001104659-21-112111 · tm2126786-7_4seq1.xml · derivative · entry 1 Rielly-Gauvin Katherine · CIK 0001791718 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-08-20 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will become fully vested on August 20, 2024. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 22:14 UTC |
Schundler RussellGeneral Counsel
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001104659-21-095511 · tm2123135-6_4seq1.xml · derivative · entry 1 Schundler Russell · CIK 0001854414 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-07-21 F1 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on July 21, 2025; provided, however, that notwithstanding the foregoing vesting schedule, 50% of the shares of common sock underlying the option will vest upon U.S. Food and Drug Administration (FDA) tentative approval of the Issuer's New Drug Application for LIQ861. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 18:15 UTC |
Shah TusharCMO and Head of R&D
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001104659-21-095512 · tm2123135-7_4seq1.xml · derivative · entry 1 Shah Tushar · CIK 0001487632 · CMO and Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-07-21 F1 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on July 21, 2025; provided, however, that notwithstanding the foregoing vesting schedule, 50% of the shares of common sock underlying the option will vest upon U.S. Food and Drug Administration (FDA) tentative approval of the Issuer's New Drug Application for LIQ861. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 18:12 UTC |
Lippe Robert AChief Operations Officer
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001104659-21-095509 · tm2123135-4_4seq1.xml · derivative · entry 1 Lippe Robert A · CIK 0001600757 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-07-21 F1 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on July 21, 2025; provided, however, that notwithstanding the foregoing vesting schedule, 50% of the shares of common sock underlying the option will vest upon U.S. Food and Drug Administration (FDA) tentative approval of the Issuer's New Drug Application for LIQ861. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 22:11 UTC |
Kaseta MichaelChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001104659-21-095508 · tm2123135-3_4seq1.xml · derivative · entry 1 Kaseta Michael · CIK 0001724346 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-07-21 F1 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on July 21, 2025; provided, however, that notwithstanding the foregoing vesting schedule, 50% of the shares of common sock underlying the option will vest upon U.S. Food and Drug Administration (FDA) tentative approval of the Issuer's New Drug Application for LIQ861. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 22:10 UTC |
Adair JasonV.P. Crp Dvlpmnt and Strtgy
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001104659-21-095504 · tm2123135-1_4seq1.xml · derivative · entry 1 Adair Jason · CIK 0001747055 · V.P. Crp Dvlpmnt and Strtgy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-07-21 F1 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on July 21, 2025; provided, however, that notwithstanding the foregoing vesting schedule, 50% of the shares of common sock underlying the option will vest upon U.S. Food and Drug Administration (FDA) tentative approval of the Issuer's New Drug Application for LIQ861. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 22:13 UTC |
Moomaw ScottSVP, Commercial
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001104659-21-095510 · tm2123135-5_4seq1.xml · derivative · entry 1 Moomaw Scott · CIK 0001832592 · SVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-07-21 F1 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on July 21, 2025; provided, however, that notwithstanding the foregoing vesting schedule, 50% of the shares of common sock underlying the option will vest upon U.S. Food and Drug Administration (FDA) tentative approval of the Issuer's New Drug Application for LIQ861. Read SEC document |
| July 21, 2021 Filed Jul 23, 2021 22:11 UTC |
deGoa DamianDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001104659-21-095507 · tm2123135-2_4seq1.xml · derivative · entry 1 deGoa Damian · CIK 0001836165 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-07-21 F1 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter, becoming fully vested on July 21, 2025; provided, however, that notwithstanding the foregoing vesting schedule, 50% of the shares of common sock underlying the option will vest upon U.S. Food and Drug Administration (FDA) tentative approval of the Issuer's New Drug Application for LIQ861. Read SEC document |
| July 06, 2021 Filed Feb 15, 2022 02:16 UTC |
Manning Paul BDirector · 10% owner
|
GiftCommon Stock | 3,921,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-009600 · doc5.xml · nonDerivative · entry 2 Manning Paul B · CIK 0001494695 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,658,721 F2 · ownership.nature: The securities are held by PD Joint Holdings, LLC Series 2016-A ("PD"). The Reporting Person is a co-manager of Tiger Lily Capital, LLC ("Tiger Lily"), the manager of PD, and has shared voting and investment power with respect to the shares held by PD. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.